Jan 8 (Reuters) - Cellectar Biosciences said on Monday its therapy iopofosine for Waldenstrom's macroglobulinemia, a type of blood cancer, met the main goal when tested in patients who received at least two prior lines of therapy. (Reporting by Christy Santhosh; Editing by Shounak Dasgupta)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
The $50 million purchase could turn into Nvidia's biggest investment.
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
These proven wealth builders could be exactly what you're searching for right now.
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
There are benefits to investing in stocks that have reasonable multiples and aren't as dependent on future earnings growth to justify their valuations.
The JPMorgan Nasdaq Equity Premium Income ETF offers a compelling blend of income and upside to my portfolio.
$10,000 to each of these companies could deliver major returns over the next decade.
Jamie Dimon and Jerome Powell are taking the European viewpoint on soaring debt levels in the U.S.